RESUMO
Ischemic stroke is a main complication of atrial fibrillation (cardiac arrhythmia). The aim of our study was to estimate the effects of citicoline (CDP-choline) therapy on the levels of circulating neurospecific protein markers in serum of the patients with ischemic stroke and atrial fibrillation. Fiftyfour patients (mean age 76 years) treated with citicoline in a dose of 2.0 g daily intravenously for 12 to 14 days in addition to basic treatment formed the examined group. Thirty-two patients (mean age 68.5 years) obtained only standard therapy and formed the control group. Serum levels of neuronal and glial protein markers, including glial fibrillary acidic protein (GFAP), a neurofilament light subunit (NF-L), myelin basic protein (MBP), and ionized calcium-binding adaptor molecule 1 (Iba1), were measured in patients of both groups before and after treatment; an immunoblotting technique followed by densitometry analysis were used. Supplementary citicoline treatment provided significant reductions of the levels of GFAP (33%, P = 0.034), NF-L (27%, P = 0.019), and MBP (32%, P = 0.018), as compared to the initial values, while there were no marked changes in the studied parameters in the control group. The results obtained allow us to hypothesize that therapeutic benefit of citicoline in patients with ischemic stroke and atrial fibrillation can be mediated through increasing neuronal viability, protecting against axonal injury, decreasing the level of reactive astrogliosis, preventing deficiencies in the blood-brain integrity, and reducing the intensity of demyelination. However, citicoline administration exerted no effect on the blood content of microglial marker Iba-1, thus possibly preserving an important functional significance of microglia, which is needed to resolve local inflammation and clear cellular debris, and also provide protective factors to reduce cell injury in the ischemic brain. The obtained results indicate that serum levels of neurospecific biomarkers are significant and clinically relevant indices of the efficiency of treatment of the above-mentioned pathologies and can be used for further investigations of the stroke pathophysiology and molecular mechanisms of nootropic-mediated neuroprotection.
RESUMO
Pericellular plasmin generation triggers apoptosis/anoikis in normal adherent cells. However, cancer cells are notoriously resistant to anoikis, enabling metastasis and new tumor growth beyond their original environment. Autophagy can be a major contributor to anoikis resistance in cancer. AIM: To investigate if protective autophagy can be induced in lung adenocarcinoma cells in response to plasminogen treatment. MATERIALS AND METHODS: Human lung adenocarcinoma A549 cells were incubated with Glu-plasminogen (0.1-1.0 µM) for 24 h. Pericellular plasmin activity was monitored spectrophotometrically by a cleavage of the specific chromogenic- substrate S-2251. Cell survival was assessed by 3-[4,5-dimethyl thiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)-test. Degradation of fibronectin, levels of autophagy markers (beclin-1 and light chain 3 (LC3)) and glycolysis regulator (TIGAR) were evaluated by western blot. Intracellular localization of LC-3 was visualized by immunocytochemistry. RESULTS: It was shown that plasminogen is converted into plasmin on the surface of adenocarcinoma cells in a dose-dependent manner. Plasmin disrupted cellular adhesive contacts resulting in cell detachment. A549 cells did not loss their viability after plasminogen treatment for 24 h, while 1.0 µM plasminogen was cytotoxic for non-transformed fibroblasts. Plasminogen 0.1, 0.5, and 1.0 µM induced 7.08-, 5.18-, and 3.78-fold elevation of TIGAR expression (p < 0.05), respectively. Enhanced TIGAR expression indicates switch on pentose phosphate pathway, protection against oxidative stress to prevent apoptosis, facilitation of DNA repair and the degradation of their own organelles (autophagy). Exposure of adenocarcinoma cells to plasminogen in concentrations of 0.1 and 0.5 µM caused 1.74- and 2.19-fold elevation of beclin-1 expression vs untreated cells (p < 0.05), respectively. Unlike K1-3 fragment, plasminogen treatment (0.1-0.5 µM) resulted in increased expression of LC3-I and stimulated rapid conversion of LC3-I to LC3-II. Up-regulation of beclin-1 levels and enhanced LC3-I/II conversion in plasminogen-treated A549 cells are the hallmarks of autophagy induction. According to immunocytochemistry data, increased LC3 puncta and autophagosome formation after exposure to plasminogen could reflect autophagy activation. CONCLUSIONS: Therefore, we showed stimulation of prosurvival signals and induction of autophagy in plasminogen-treated adenocarcinoma cells rendering them resistant to apoptosis/anoikis. Based on the obtained data, autophagy has a great potential for novel targets that affect cancer cell death, in addition to the current cytotoxic agents.
Assuntos
Proteínas Reguladoras de Apoptose/genética , Autofagia , Fibrinolisina/metabolismo , Regulação Neoplásica da Expressão Gênica , Monoéster Fosfórico Hidrolases/genética , Plasminogênio/metabolismo , Células A549 , Adenocarcinoma de Pulmão/genética , Adenocarcinoma de Pulmão/metabolismo , Proteínas Reguladoras de Apoptose/metabolismo , Autofagia/efeitos dos fármacos , Autofagia/genética , Biomarcadores , Linhagem Celular Tumoral , Ativação Enzimática , Fibrinolisina/farmacologia , Expressão Gênica , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Glicólise , Humanos , Monoéster Fosfórico Hidrolases/metabolismo , Plasminogênio/farmacologiaRESUMO
We have investigated effects of letrozole, an aromatase inhibitor, on spatial learning and memory, expression of neural cell adhesion molecules (NCAM) and catecholaminergic neurotransmitters in the hippocampus and cortex of female rats. In the intact model, adult Sprague-Dawley rats were divided into four groups (n=8). Control received saline alone. Letrozole was administered to the animals in the second and third groups by daily oral gavage at 0.2 and 1 mg/kg doses, respectively, for 6 weeks. Another group of letrozole-treated rats was allowed to recover for 2 weeks. In the second model, 24 rats were ovariectomized (ovx) and the first group served as control. The second group received letrozole (1 mg/kg) for 6 weeks. Ovx rats in the third group were given letrozole (1 microg/kg) plus estradiol (E(2)) (10 microg/rat). At the end, all rats were tested in a spatial version of the Morris water maze. Then they were decapitated and the brains rapidly removed. Catecholamine concentrations were determined by high performance liquid chromatography with electrochemical detection. NCAM 180, 140 and 120 isoforms were detected by Western blotting. Uterine weights were significantly reduced by letrozole in a dose-dependent manner (P<0.01) which returned to control values following 2 weeks of recovery (P<0.05). Serum E(2) levels followed a similar course (P<0.01). Although improvement in spatial learning performance of letrozole-treated rats was not statistically significant, the high-dose letrozole-treated group remained significantly longer in the target quadrant compared with the control (P<0.05). Administration of letrozole to ovx animals significantly reduced the latency (P<0.001) and increased the probe trial performance compared with ovx controls (P<0.05). Letrozole increased expression of NCAM 180 and NCAM 140 in both hippocampus and cortex of intact rats. In the cortex samples of ovx animals, NCAM 180 was overall lower than the intact control values (P<0.05). Noradrenaline, dopamine and their metabolites were decreased in the hippocampus of the letrozole-treated group (P<0.01). Letrozole had differential effects on noradrenaline and dopamine content in the cortex. It appears that inhibition of estrogen synthesis in the brain may have beneficial effects on spatial memory. We suggest that structural changes such as NCAM expression and catecholaminergic neurotransmitters in the hippocampus and prefrontal cortex may be the neural basis for estrogen-dependent alterations in cognitive functions.
Assuntos
Inibidores da Aromatase/farmacologia , Catecolaminas/fisiologia , Córtex Cerebral/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Aprendizagem/efeitos dos fármacos , Memória/efeitos dos fármacos , Moléculas de Adesão de Célula Nervosa/biossíntese , Neurotransmissores/metabolismo , Nitrilas/farmacologia , Sistema Nervoso Parassimpático/efeitos dos fármacos , Percepção Espacial/efeitos dos fármacos , Triazóis/farmacologia , Animais , Western Blotting , Córtex Cerebral/metabolismo , Cromatografia Líquida de Alta Pressão , Densitometria , Dopamina/metabolismo , Eletroquímica , Estradiol/farmacologia , Feminino , Hipocampo/metabolismo , Letrozol , Aprendizagem em Labirinto/efeitos dos fármacos , Norepinefrina/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Ovariectomia , Ovário/efeitos dos fármacos , Ratos , Útero/efeitos dos fármacos , Aumento de Peso/efeitos dos fármacosRESUMO
The chronic effects of low doses of cadmium on the distribution of soluble and filament forms of glial fibrillary acidic protein (GFAP) and their polypeptide fragments in different parts of the rat brain were investigated. Obtained results showed dose-dependent effect of cadmium on the soluble form of GFAP and more pronounced effect on the filament form and composition of the polypeptide fragments of the protein in the rat brain. Prolonged intoxication by cadmium ions in a dose of 1.0 µg/kg of body weight induced a significant decrease in soluble GFAP and an increase in the filament form in the rat brain, pointing to the development of reactive astrogliosis and the risk of neurodegeneration.
Assuntos
Cloreto de Cádmio/toxicidade , Cerebelo/efeitos dos fármacos , Poluentes Ambientais/toxicidade , Proteína Glial Fibrilar Ácida/metabolismo , Tálamo/efeitos dos fármacos , Administração Oral , Animais , Cerebelo/metabolismo , Relação Dose-Resposta a Droga , Fragmentos de Peptídeos/metabolismo , Ratos Wistar , Tálamo/metabolismoRESUMO
Neural cell adhesion molecules (NCAMs) are members of the immunoglobulin superfamily and are involved in synaptic rearrangements in the mature brain. There are three major NCAM forms: NCAM 180, NCAM 140 and NCAM 120. Several studies report that NCAMs play a central role in memory. In the present study we investigated the effects of melatonin on the expression of NCAMs in the hippocampus, cortex and cerebellum. The levels of NCAMs were determined by Western blotting. After administration of melatonin for 7 days, NCAM 180 expression increased both in the hippocampus and in the cortex as compared to controls. On the contrary, in rats exposed to the constant light for 7 days (which inhibits endogenous production of melatonin), NCAM 180 levels decreased in the hippocampus and became undetectable in cortex and cerebellum. NCAM 140 levels were also diminished in the hippocampus of constant light-exposed rats. There was no change in NCAM 120 expression in any brain regions. This is the first report indicating that melatonin has a modulatory effect on the expression of NCAM in brain areas concerned with cognitive function. Melatonin may be involved in structural remodeling of synaptic connections during memory and learning processes.
Assuntos
Córtex Cerebral/metabolismo , Hipocampo/metabolismo , Melatonina/fisiologia , Moléculas de Adesão de Célula Nervosa/metabolismo , Animais , Western Blotting , Cerebelo/metabolismo , Cerebelo/efeitos da radiação , Córtex Cerebral/efeitos da radiação , Hipocampo/efeitos da radiação , Luz , Masculino , Isoformas de Proteínas/metabolismo , Ratos , Ratos Wistar , Valores de Referência , Fatores de TempoRESUMO
The present study examined the protective effects of vitamin E against aluminum-induced neurotoxicity in rats. Wistar rats were given daily aluminum via their drinking water containing 1600 mg/liter aluminum chloride for six weeks. Aluminum induced a significant increase in lipid peroxidation (LPO) in hippocampus and frontal cortex. Furthermore, aluminum caused marked elevation in the levels of the glial markers (glial fibrillary acidic protein (GFAP) and S100B) and proinflammatory cytokines (TNF-alpha and IL-1beta) in both brain areas. Vitamin E treatment reduced the contents of glial markers and cytokines and the levels of LPO. In conclusion, this study demonstrates that vitamin E ameliorates glial activation and reduces release of proinflammatory cytokines induced by aluminum.